Abstract
Background Pyroptosis has been drawn attention owing to its contributory role in various cancers. Recently, the participator of pyroptosis, gasdermins (GSDMs) have been reported associated with of multiple types of cancers. However, the role of GSDMs expression in diagnosis and prognosis of gastric cancer (GC) has not been well elucidated. Moreover, the mechanisms underlying the carcinogenesis of GC are still obscure.
Methods Herein we analyzed the transcriptional, prognostic information and the role of GSDMs in patients with GC from TIMER, UALCAN, Human Protein Atlas (HPA), GEPIA and Kaplan-Meier plotter databases. The cBioPortal online tool was used to analyze the GSDMs alterations, correlations, and networks. Furthermore, String, Cytoscape and TIMER were conducted to explore the functional enrichment and immune modulation. The statistical analysis was carried out in the R environment, and P-value < 0.05 was considered statistically significant.
Results GSDMB, GSDMC, GSDMD, GSDME were with higher expression in GC than normal tissue in TIMER database. Moreover, survival analyses via two databases both demonstrated that high expression of GSDME was related to shorter overall survival (OS) in patients with GC. Additionally, functional enrichment revealed that GSDMs might be involved in endopeptidase activity, peptidase regulator activity, cysteine-type peptidase activity. Besides, GSDMs were correlated with infiltration levels of immune cells in GC, and GSDME was correlated with the infiltrating level of CD4+ T, CD8+ T, neutrophils, macrophages and dendritic cells.
Conclusions The study systematically indicated the potential diagnostic and prognostic value of GSDMs in GC. Our results showed that GSDME might play a considerably oncogenic role in GC diagnosis and prognosis. However, our bioinformatics analyses should be further validated in more prospective studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Changshu Medicine Examination Insitute
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files
